The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism
about
Biopersistence and brain translocation of aluminum adjuvants of vaccinesT-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injectionThe Autoimmune EcologyChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesFusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primatesSafety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.Do early childhood immunizations influence the development of atopy and do they cause allergic reactions?A practical approach to immunization in atopic children.Review of L-tyrosine confirming its safe human use as an adjuvant.Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88Towards an understanding of the adjuvant action of aluminium.Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosisInterleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titersCathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants.Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environmentAluminum is a potential environmental factor for Crohn's disease induction: extended hypothesis.Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.Design of nanoparticle-based dry powder pulmonary vaccines.Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.Superovulation with a single administration of FSH in aluminum hydroxide gel: a novel superovulation method for cattle.Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticlesFrom vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease.Current adjuvants and new perspectives in vaccine formulation.How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population.The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.Clinical use of adjuvants in allergen-immunotherapy.Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature.Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitroMalaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Immunomodulation in human dendritic cells leads to induction of interferon-gamma production by Leishmania donovani derived KMP-11 antigen via activation of NF-κB in Indian kala-azar patientsMechanism of immunopotentiation and safety of aluminum adjuvants.Characterization of hematopoietic potential of mesenchymal stem cells.Dendritic cells infected with adenovirus expressing the thyrotrophin receptor induce Graves' hyperthyroidism in BALB/c mice.A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine.Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells.A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei.
P2860
Q21129422-9909F06E-94B4-4AD9-8BB4-9C4D7240B8B0Q24645758-B5B82925-CA3A-45B3-993A-AB37BB73176CQ26747427-403A2697-6D3A-46BB-BB9A-917900DE19F0Q26783488-26A4F7DE-332F-471D-8150-0CF531B0D7FDQ27306708-A5435E4B-B8B8-4AAC-B281-DEA4A293FA39Q33394245-FCD1F538-3CE2-47E8-9C8D-3A8B19A60BECQ33552269-200E2794-6F09-4B63-B4E1-2DAC4A655D78Q33805176-871CA23F-63A8-4DB5-80F6-D23085D9811BQ34532620-1E9A38AB-D99F-4EAB-A613-23EFAC084B07Q34655443-195615D5-A27F-42B6-9DD5-458C9B2449ECQ34923189-B09FCE4C-2FBD-45BE-BC5C-712BAE27D438Q35090905-88B23744-AA6D-40D7-90DE-0D9EC0C7586CQ35138579-3F9AE108-51FF-4029-9A66-733E59A1596AQ35521010-6467AA5C-F763-48B5-83B0-6F44B3EF1156Q36422563-CABB14EA-E972-4E8D-A350-860372100AFEQ36685124-1C865D8B-2816-4264-A6F6-A855B946E698Q36744330-04EC98D7-60E5-4C97-B106-022AC4C572A3Q36766169-04E9E77A-270F-4EA4-ABE3-3D39FBEB097AQ36931389-E6F60BD9-04B9-4631-8552-288CC987C075Q36968256-0D2C2228-11D3-4EF3-8FC6-15F1515B1671Q36985908-D6C09B50-B73D-4A73-B1E2-F45CEBDB7C4EQ37036694-C4F429E3-80E5-43EF-9FC7-54F953F6E162Q37369699-BB74B853-DB83-4603-A21A-D23FEE895EC7Q37461020-306FC1B8-B339-4AD0-BB85-987B7EA31625Q37571922-41806B62-5711-4C54-A088-051072F4B691Q37837477-6772430E-FE20-4356-B470-50B99B383632Q37909424-E0FA7A6C-EAFB-4E56-8F5A-F629E1D53589Q38042446-E5B905C5-82BC-41DA-A6A6-9B14E8A4E2FCQ38453147-E1767A5A-0618-459A-B685-7CD961514F3AQ38761412-BA968867-0F84-4DB0-B6C4-E368CE7C6EB8Q38902486-3A9B8D8B-4B33-404C-AE64-CFD3C8398838Q39597125-3CE2684E-76B2-4503-8F31-3722C7BE28C8Q40752357-DC3B4345-EDAE-4048-9BDB-FC774BB56439Q41939228-C14758B3-C3A8-4278-85AE-4C84B8E9CA82Q42036323-FC6611D4-9D33-4DB6-A21B-0401BAC90241Q42968664-B5F00235-985C-4139-A1D0-7080E38414F7Q44299562-E719D979-8843-4CCC-9773-5EC93C747FC7Q44348323-BBE6F7CF-7D2D-4D94-B11A-4B43C1C12214Q45043926-6C955638-54EB-4A90-A41D-BE09A0D8DDE1Q47875209-A85BB8A3-259B-494F-A8FB-E803F6E04038
P2860
The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@ast
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@en
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@nl
type
label
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@ast
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@en
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@nl
prefLabel
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@ast
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@en
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@nl
P2093
P2860
P921
P3181
P1476
The Common vaccine adjuvant al ...... erleukin-4-dependent mechanism
@en
P2093
A Tarkowski
L A Hanson
M Hahn-Zoric
P2860
P304
P3181
P356
10.1128/IAI.69.2.1151-1159.2001
P407
P577
2001-02-01T00:00:00Z